Niagen Bioscience, Inc.
NAGE· Nasdaq
NAGENiagen Bioscience, Inc.
Filed Mar 7, 2019 · 10-K · 66 days after period end · 0001654954-19-002395
derived · Computed from the longer spans the company filed.
| Metric | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $9.07M | $7.53M | $4.45M | $4.36M |
| Net Income | -$8.22M | -$8.82M | -$2.15M | -$1.43M |
| EPS Diluted | — | -$0.17 | -$0.06 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
ended Dec 31, 2018 · filed Mar 7, 2019 · 66 d after period end
